Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
1 finding from 1 review
RR 0.71 [0.46, 1.1]
110 participants
Low
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes clinical relapse compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Sulphasalazine showed no clear difference in clinical relapse compared with placebo (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical relapse compared with anti TNF‐α (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical relapse compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in clinical relapse (at 52 weeks, HBI > 4) compared with biosimilar (low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Intervention diet showed no clear difference in clinical relapse at 6 to 24 months ‐ Symptoms‐guided diet compared with control diet (low certainty).
4 findings from 1 review
RR 0.53 [0.28, 1.01]
2 studies · 98 participants
Low
RR 1.03 [0.85, 1.26]
1 study · 214 participants
Low
RR 0.11 [0.01, 1.76]
1 study · 54 participants
Very low
Show 1 more finding